Earnings Call Intelligence Subscribe
Home › Call Sheets › MRK › Q2'26
Call sheet · Q2'26

Merck (MRK)

Q2'26 earnings call · held August 4, 2026 · compared with the Q1'26 call · management-credibility review
10/12
Disclosure score
6 medium, 1 low flags
Financial quality
Bottom line
The sleeper story is what didn't get said: last quarter's AI transformation push (Google Cloud, Tempus, Mayo) completely vanished from this call, right as gross margin compressed for a second straight quarter on unquantified inventory reserves and OpEx growth tripled to outpace revenue. The obvious headline, a beat-and-raise on $16.6B revenue with pipeline de-risking ahead of schedule, is real, but the binding constraint is shifting from 'can the pipeline replace Keytruda' to 'how fast does Keytruda actually decelerate,' and management just told you the answer themselves: 'we anticipate that total U.S. Keytruda year-over-year growth will moderate as we increasingly reach peak penetration'. Otovair's quiet one-year slip from 'accelerate in H2 2026' to 'accelerate in 2027' while the tone stays unchanged is a tell that near-term execution is harder than the narrative admits. My view changes if next quarter brings a quantified inventory reserve figure, a resumption of AI commentary with real KPIs, or evidence that Otovair's 2027 acceleration target is itself slipping.

The 30-second version

  • The AI story just vanished without a word
  • Beat-and-raise headline masks an explicit Keytruda deceleration call
  • Otovair's 'acceleration' promise just got pushed a full year, with zero change in tone

What changed this quarter

MetricQ1'26Q2'26Change
Total Revenue (ex-FX growth)$16.3B, +3% ex-FX$16.6B, +4% ex-FX+100bps acceleration
Keytruda family growth+8% ex-FX to $8.0B+4% ex-FX to $8.4BGrowth rate cut in half
Keytruda Qlex sales$128M$463M+262% q/q, largely J-code timing
WelliReg sales$199M, +43%$271M, +67%Growth rate accelerating
Gardasil sales$1.1B, -22%$1.2B, +3%Reversed from decline to growth
Capvaxive sales$142M, +31%$184M, +40%Growth rate accelerating
Winrevair sales$525M$588M, +75%Still ramping strongly
Otovair sales$131M$204MBoosted by specialty-pharmacy timing set to unwind in Q3
Non-GAAP gross margin81.9%81.1%-80bps, 2nd straight quarter of inventory-reserve drag
OpEx growth ex-charges+2% YoY+7% YoYMore than tripled, now outpacing revenue growth

Accountability tracked

6 new promises made3 narrative shifts flagged7 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full MRK Q2'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.